Trial Profile
A single center, randomized, double blind, in parallel clinical study to compare pharmacokinetics profile of testing drug to originator, with a single dose of Recombinant anti TNF-alpha Human Mouse Chimeric Monoclonal Antibody andRemicade in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Autoimmune disorders
- Focus Pharmacokinetics
- Sponsors Genor Biopharma
- 03 Dec 2018 Status changed to completed as per results published in the BioDrugs.
- 03 Dec 2018 Results published in the BioDrugs
- 03 May 2016 New trial record